

HEPATOBIILIARY DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
 ROOM: ROSSETTI
 SATURDAY MAY 4, 2019, 11:40 AM – 12:30 PM

CO-CHAIRS : DR. JENNIFER KNOX & DR. OLIVER BATHE
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with hepatobiliary malignancies in Canada.
- To identify clinical trial research opportunities in hepatobiliary malignancies within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to hepatobiliary malignancies.
- To integrate and apply new clinical trial methodologies in hepatobiliary malignancies in the Canadian Cancer Trials Group research agenda.
- To provide a learning and mentoring environment supportive to new investigators.

11:40 am	Welcome	Dr. J. Knox Dr. O. Bathe
11:45 am	Adjuvant Biliary Concepts: <ul style="list-style-type: none"> • UNICANCER - mFOLFIRINOX vs capecitabine for resected biliary tract cancers: A randomized Phase III trial • SWOG - Gemcitabine and Capecitabine vs Capecitabine +/- Radiotherapy in R1 Resected Adjuvant Biliary Cancer 	Dr. J. Knox

12:00 pm	SULTAN (PRODIGE 53): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy	Dr. D. Jonker Dr. P. Karanicolos
12:05 pm	Concept: BATCH – Biliary Basket Trial	Dr. J. Knox
12:15 pm	Concept: Oligomets/SBRT	Dr. L. Dawson
12:20 pm	HE. 1: Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases	Dr. L. Dawson
12:25 pm	Intergroup Task Force Update	Dr. J. Knox Dr. O. Bathe
12:30 pm	Meeting Adjourned	